Laurus Labs, a pharma company, is showing signs of recovery after a recent dip. Experts suggest short-term traders with a high-risk profile can consider buying the stock. A target of Rs 1,120 is anticipated in the coming weeks. Technical indicators point towards positive momentum. The stock has reclaimed key moving averages and shows bullish signals.
